U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799273) titled 'MECKI-Amyloidosis: Assessment of the Exercise Capacity and Prognosis of Patients with Cardiac Amyloidosis' on Jan. 23.
Brief Summary: This study aims to advance the understanding of cardiac amyloidosis, its effects on exercise capacity, and its prognostic implications. By conducting a systematic investigation with particular emphasis on longitudinal evaluation, we aim to provide valuable insights to guide clinical practice and improve the management of patients with cardiac amyloidosis.
Our study intends to follow patients for a period of two years, evaluating them every six months. This longitudinal approach allows us to monitor c...